B&L Sees Visudyne Coverage Loss As Envision Gain; Market Rebound In Sight
This article was originally published in The Gray Sheet
Executive Summary
Bausch & Lomb views CMS' decision not to cover QLT's Visudyne for age-related macular degeneration in patients with occult lesions as a net positive for the company, which is developing a treatment of its own
You may also be interested in...
QLT/Novartis Visudyne Occult Data Expected 2004; Medicare Coverage Denied
QLT expects to have data on Visudyne in age-related macular degeneration patients with occult lesions from an ongoing Canadian and European trial by 2004
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.